Intensive Care Management of Multiorgan Dysfunction and Hypoxic Brain Injury Secondary to Refractory Status Epilepticus
Abstract
Refractory Status Epilepticus (RSE) is a medical emergency that may lead to permanent brain damage or death.
Mortality rate is 16-39%. It is the life threatening condition in which continuous fits occur, despite treatment
with benzodiazepines and one antiepileptic drug.
A 25-year-old female, brought in emergency department with high-grade fever and frequent fits. Glasgow
Coma Scale (GCS) was 3/15 with unstable hemodynamics. Resuscitation started immediately and managed as
status epilepticus. Patient was in multi organ failure on arrival. On the basis of history and examination, hypoxic
brain injury was diagnosed initially. Later on, refractory status epilepticus (RSE) with multi organ dysfunction
syndrome (MODS) was diagnosed, after necessary investigations and treatment. Patient was managed as a
team with multidisciplinary approach and after continuous effort of 2 weeks, patient was successfully
discharged to home.
References
Kantanen AM, Kälviäinen R, Parviainen I, Ala-Peijari M, Bäcklund T, Koskenkari J, et al. Predictors of hospital and one-year mortality in intensive care patients with refractory status epilepticus: a population-based study. Critical Care. 2017; 21: 71.
Harris C, Gilmore E. Seizures and Status Epilepticus. In Neurocritical Care for the Advanced Practice Clinician.
Springer, Cham. 2018; pp: 201-21.
Reynolds AS, Claassen J. Treatment of seizures and postanoxic status epilepticus. In Seminars in neurology.
Thieme Medical Publishers. 2017; 37: 033-9
Gaxiola-Valdez I, Singh S, Perera T, Sandy S, Li E, Federico P. Seizure onset zone localization using postictal
hypoperfusion detected by arterial spin labelling MRI. Brain. 2017; 140: 2895-911.
Bauer G, Unterberger I. Anoxic Myoclonic Status Epilepticus. InStatus Epilepticus. Springer, Cham. 2018; pp:
-65.
Madžar D, Reindl C, Giede-Jeppe A, Bobinger T, Sprügel MI, Knappe RU, et al. Impact of timing of continuous
intravenous anesthetic drug treatment on outcome in refractory status epilepticus. Critical Care. 2018; 22: 317.
Schmutzhard E, Pfausler B. Complications of the management of status epilepticus in the intensive care unit.
Epilepsia. 2011; 52: 39-41.
Bellante F, Legros B, Depondt C, Créteur J, Taccone FS, Gaspard N. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. Journal of neurology. 2016; 263: 799-806.
Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurologica Scandinavica. 2017; 135: 92.
Reznik ME, Berger K, Claassen J. Comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus. Journal of clinical medicine. 2016; 5: 54.
Lehtimäki K, Långsjö JW, Ollikainen J, Heinonen H, Möttönen T, Tähtinen T, et al. Successful management of
super-refractory status epilepticus with thalamic deep brain stimulation. Annals of neurology. 2017; 81: 142-6.
Beretta S, Coppo A, Bianchi E, Zanchi C, Carone D, Stabile A, et al. Neurologic outcome of postanoxic refractory status epilepticus after aggressive treatment. Neurology. 2018; 91: e2153-62.
Hocker S. Treatment of Refractory and Super-Refractory Status Epilepticus. InStatus Epilepticus. Springer, Cham. 2018; pp: 201-14.
Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia. 2017; 58: 1533-41.
Rossetti AO, Hirsch LJ, Drislane FW. Nonconvulsive seizures and nonconvulsive status epilepticus in the neuro ICU should or should not be treated aggressively: A debate. Clinical Neurophysiology Practice. 2019; 4: 170-7.
Holtkamp M. Pharmacotherapy for refractory and super refractory status epilepticus in adults. Drugs. 2018; 78: 307- 26.
